SG11202002579SA - Preparation and storage of liposomal rna formulations suitable for therapy - Google Patents
Preparation and storage of liposomal rna formulations suitable for therapyInfo
- Publication number
- SG11202002579SA SG11202002579SA SG11202002579SA SG11202002579SA SG11202002579SA SG 11202002579S A SG11202002579S A SG 11202002579SA SG 11202002579S A SG11202002579S A SG 11202002579SA SG 11202002579S A SG11202002579S A SG 11202002579SA SG 11202002579S A SG11202002579S A SG 11202002579SA
- Authority
- SG
- Singapore
- Prior art keywords
- therapy
- preparation
- storage
- formulations suitable
- rna formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574965P | 2017-10-20 | 2017-10-20 | |
| PCT/EP2018/078587 WO2019077053A1 (en) | 2017-10-20 | 2018-10-18 | Preparation and storage of liposomal rna formulations suitable for therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002579SA true SG11202002579SA (en) | 2020-05-28 |
Family
ID=63965663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002579SA SG11202002579SA (en) | 2017-10-20 | 2018-10-18 | Preparation and storage of liposomal rna formulations suitable for therapy |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11395799B2 (en) |
| EP (2) | EP3858333A1 (en) |
| JP (2) | JP2021500324A (en) |
| KR (1) | KR20200100619A (en) |
| CN (3) | CN114392233A (en) |
| AR (2) | AR113782A1 (en) |
| AU (2) | AU2018350846B2 (en) |
| BR (1) | BR112020007470A2 (en) |
| CA (1) | CA3078292A1 (en) |
| IL (1) | IL273852A (en) |
| MX (2) | MX2020003413A (en) |
| RU (1) | RU2022103533A (en) |
| SG (1) | SG11202002579SA (en) |
| TW (2) | TW201927288A (en) |
| WO (1) | WO2019077053A1 (en) |
| ZA (1) | ZA202001675B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI472339B (en) | 2008-01-30 | 2015-02-11 | Genentech Inc | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
| BRPI0812682A2 (en) | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
| EP3589661B1 (en) | 2017-03-02 | 2023-11-01 | Genentech, Inc. | Adjuvant treatment of her2-positive breast cancer |
| JP2021500324A (en) | 2017-10-20 | 2021-01-07 | バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ | Preparation and storage of therapeutically suitable liposome RNA preparations |
| WO2019141814A1 (en) * | 2018-01-18 | 2019-07-25 | Etherna Immunotherapies Nv | Lipid nanoparticles |
| WO2020200472A1 (en) * | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Preparation and storage of liposomal rna formulations suitable for therapy |
| BR112023004247A2 (en) | 2020-09-08 | 2023-04-11 | Genentech Inc | PIPE KITS FOR FORMING A MIXTURE, SYSTEMS FOR FORMING A PHARMACEUTICAL COMPOSITION, METHODS FOR TRANSFERRING PHARMACEUTICAL COMPOSITIONS AND FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION AND PULSE DAMPER |
| TW202228727A (en) * | 2020-10-01 | 2022-08-01 | 德商拜恩迪克公司 | Preparation and storage of liposomal rna formulations suitable for therapy |
| BR112023016897A2 (en) * | 2021-02-23 | 2023-11-21 | Natures Toolbox Inc | ENCAPSULATION OF LIPID NANOPARTICLES (LNP) OF MRNA PRODUCTS |
| EP4334944A1 (en) | 2021-05-04 | 2024-03-13 | BioNTech SE | Immunogen selection |
| CA3223943A1 (en) | 2021-07-29 | 2023-02-02 | Ugur Sahin | Compositions and methods for treatment of melanoma |
| EP4412591A1 (en) | 2021-10-06 | 2024-08-14 | leon-nanodrugs GmbH | Method for preparing lipid nanoparticles |
| CN114601747A (en) * | 2022-03-07 | 2022-06-10 | 广州市万千粉丝化妆品有限公司 | Application of nucleoprotein telomerase with functions of promoting growth of protein and RNA, prolonging cell telomere and proliferating in cosmetics |
| WO2024011033A1 (en) | 2022-07-07 | 2024-01-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogens and methods for inducing an immune response |
| WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE286719T1 (en) * | 1999-07-15 | 2005-01-15 | Inex Pharmaceuticals Corp | METHOD FOR PRODUCING THERAPEUTIC ACTIVE INGREDIENTS ENCAPSULATED IN LIPID |
| DE10109897A1 (en) | 2001-02-21 | 2002-11-07 | Novosom Ag | Optional cationic liposomes and their use |
| JP4550421B2 (en) * | 2001-12-12 | 2010-09-22 | メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド | Composition for the preservation of viruses |
| US7008403B1 (en) | 2002-07-19 | 2006-03-07 | Cognitive Ventures Corporation | Infusion pump and method for use |
| CN1798545B (en) | 2003-06-04 | 2013-06-05 | 乔治敦大学 | Method for improving stability and shelf-life of liposome complexes |
| EP1512393A1 (en) * | 2003-09-08 | 2005-03-09 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Process for the production of homogeneous liposomes and lipoplexes |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| US20110165223A1 (en) * | 2008-01-02 | 2011-07-07 | The Johns Hopkins University | Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen |
| US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| JP2013512251A (en) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Simultaneous inhibition of PD-L1 / PD-L2 |
| EP2558074B1 (en) * | 2010-04-08 | 2018-06-06 | The Trustees of Princeton University | Preparation of lipid nanoparticles |
| JP6054308B2 (en) | 2011-02-15 | 2016-12-27 | メリマック ファーマシューティカルズ， インコーポレイテッドＭｅｒｒｉｍａｃｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Compositions and methods for delivering nucleic acids to cells |
| CN102144973A (en) | 2011-03-31 | 2011-08-10 | 中国药科大学 | Prescription composition of optimized siRNA cation liposome |
| CN102727436A (en) | 2011-04-15 | 2012-10-17 | 百奥迈科生物技术有限公司 | Nucleic acid liposome drug preparation |
| RU2647476C2 (en) | 2011-11-04 | 2018-03-15 | Нитто Денко Корпорейшн | Method of producing lipid nanoparticles for drug delivery |
| ME03367B (en) | 2012-03-26 | 2019-10-20 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Rna formulation for immunotherapy |
| WO2013143555A1 (en) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| CN103194489B (en) | 2013-03-26 | 2015-09-30 | 中国科学院过程工程研究所 | New Cationic Liposome nucleic acid drug preparation, and its preparation method and application |
| KR20160043103A (en) * | 2013-08-21 | 2016-04-20 | 큐어백 아게 | Composition and Vaccine for Treating Prostate Cancer |
| AU2013401479B2 (en) * | 2013-09-26 | 2019-04-04 | BioNTech SE | Particles comprising a shell with RNA |
| WO2016045732A1 (en) * | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| KR102626448B1 (en) * | 2015-02-24 | 2024-01-19 | 더 유니버시티 오브 브리티시 콜롬비아 | Continuous flow microfluidic systems |
| EP3271057B1 (en) * | 2015-03-19 | 2019-09-04 | The University of Connecticut | Systems and methods for continuous manufacturing of liposomal drug formulations |
| WO2016155809A1 (en) * | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
| JP2021500324A (en) | 2017-10-20 | 2021-01-07 | バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ | Preparation and storage of therapeutically suitable liposome RNA preparations |
-
2018
- 2018-10-18 JP JP2020520738A patent/JP2021500324A/en active Pending
- 2018-10-18 MX MX2020003413A patent/MX2020003413A/en unknown
- 2018-10-18 US US16/757,054 patent/US11395799B2/en active Active
- 2018-10-18 AU AU2018350846A patent/AU2018350846B2/en active Active
- 2018-10-18 KR KR1020207014348A patent/KR20200100619A/en not_active Application Discontinuation
- 2018-10-18 BR BR112020007470-5A patent/BR112020007470A2/en unknown
- 2018-10-18 CA CA3078292A patent/CA3078292A1/en active Pending
- 2018-10-18 TW TW107136678A patent/TW201927288A/en unknown
- 2018-10-18 WO PCT/EP2018/078587 patent/WO2019077053A1/en unknown
- 2018-10-18 CN CN202210003912.9A patent/CN114392233A/en active Pending
- 2018-10-18 TW TW110132980A patent/TW202146031A/en unknown
- 2018-10-18 CN CN201880068224.2A patent/CN111246845A/en active Pending
- 2018-10-18 CN CN202210004497.9A patent/CN114344486A/en active Pending
- 2018-10-18 EP EP21151194.4A patent/EP3858333A1/en active Pending
- 2018-10-18 SG SG11202002579SA patent/SG11202002579SA/en unknown
- 2018-10-18 RU RU2022103533A patent/RU2022103533A/en unknown
- 2018-10-18 EP EP18792901.3A patent/EP3697384A1/en active Pending
- 2018-10-19 AR ARP180103065A patent/AR113782A1/en unknown
-
2020
- 2020-03-17 ZA ZA2020/01675A patent/ZA202001675B/en unknown
- 2020-04-06 IL IL273852A patent/IL273852A/en unknown
- 2020-07-13 MX MX2024001218A patent/MX2024001218A/en unknown
-
2021
- 2021-02-08 US US17/170,826 patent/US12059498B2/en active Active
-
2022
- 2022-10-13 AR ARP220102789A patent/AR127361A2/en unknown
-
2023
- 2023-01-04 JP JP2023000105A patent/JP2023052184A/en active Pending
- 2023-02-28 AU AU2023201185A patent/AU2023201185A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114392233A (en) | 2022-04-26 |
| BR112020007470A2 (en) | 2020-10-27 |
| AU2018350846B2 (en) | 2022-12-08 |
| TW201927288A (en) | 2019-07-16 |
| MX2020003413A (en) | 2020-07-20 |
| IL273852A (en) | 2020-05-31 |
| CN111246845A (en) | 2020-06-05 |
| AU2023201185A1 (en) | 2023-04-06 |
| TW202146031A (en) | 2021-12-16 |
| AU2018350846A1 (en) | 2020-04-23 |
| KR20200100619A (en) | 2020-08-26 |
| CN114344486A (en) | 2022-04-15 |
| ZA202001675B (en) | 2021-07-28 |
| JP2021500324A (en) | 2021-01-07 |
| WO2019077053A1 (en) | 2019-04-25 |
| AR127361A2 (en) | 2024-01-17 |
| US20200246267A1 (en) | 2020-08-06 |
| CA3078292A1 (en) | 2019-04-25 |
| RU2020113577A (en) | 2021-11-22 |
| EP3697384A1 (en) | 2020-08-26 |
| US11395799B2 (en) | 2022-07-26 |
| US12059498B2 (en) | 2024-08-13 |
| RU2022103533A (en) | 2022-03-10 |
| JP2023052184A (en) | 2023-04-11 |
| MX2024001218A (en) | 2024-02-12 |
| EP3858333A1 (en) | 2021-08-04 |
| RU2020113577A3 (en) | 2022-02-16 |
| US20210161818A1 (en) | 2021-06-03 |
| AR113782A1 (en) | 2020-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273852A (en) | Preparation and storage of liposomal rna formulations suitable for therapy | |
| EP3621648A4 (en) | Msln targeting trispecific proteins and methods of use | |
| IL259100B1 (en) | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use | |
| ZA202001487B (en) | Liposomal formulations comprising saponin and methods of use | |
| ZA201807519B (en) | Liposomal preparation and methods of treatment | |
| EP3416671A4 (en) | Nucleic acid carriers and therapeutic methods of use | |
| IL261996A (en) | Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells | |
| IL253796A0 (en) | Therapeutically active compounds and their methods of use | |
| ZA202106237B (en) | Preparation and storage of liposomal rna formulations suitable for therapy | |
| EP3749344A4 (en) | Methods for therapeutic use of exosomes and y-rnas | |
| EP3694832A4 (en) | Extended release pharmaceutical formulation and methods of treatment | |
| EP3380525A4 (en) | Pharmaceutical formulations and methods of use thereof | |
| IL266198A (en) | Liposomal formulation for use in the treatment of cancer | |
| EP3526205A4 (en) | Therapeutic compounds and methods of use thereof | |
| EP3416691A4 (en) | Nucleic acid carriers and therapeutic methods of use | |
| IL261655B (en) | Liposomal formulations and methods of using same in agriculture | |
| EP3290034A4 (en) | Use of trimethazine in preparation of drugs for preventing and treating liver diseases | |
| SI3558391T1 (en) | Immunoconjugates targeting adam9 and methods of use thereof | |
| EP3463366A4 (en) | Topical formulations of pde-4 inhibitors and their methods of use | |
| IL266132B (en) | Pharmaceutical formulations and methods of making the same | |
| IL280000A (en) | Tumor reduction formulations and methods of use thereof | |
| EP3313520A4 (en) | Therapeutic uses of berberine formulations | |
| EP3497243A4 (en) | Cell therapy compositions and methods of use thereof | |
| EP3346989A4 (en) | Stable liposomal formulations of rapamycin and rapamycin derivatives for treating cancer | |
| EP3313427A4 (en) | Therapeutic peptides and methods of use thereof |